Why combination drug treatment ineffective in cancer clinical trials

December 5, 2013

Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

Faculty of Medicine & Dentistry researcher Michael Sawyer and his colleagues, including first author Vijaya Damaraju, recently published their findings in the peer-reviewed journal, Clinical Cancer Research.

In the '80s and '90s, cancer research focused on finding out which proteins "drove" cancers. New drugs targeting these proteins worked well by themselves, and some in the field believed combining the new drugs with the older chemotherapy drugs would work better than either drug by itself.

"So the pharmaceutical industry developed a combination of drugs in which we thought we were giving two drugs at once, but in actual fact the one drug we were giving was completely blocking the actions of the other drug," said Sawyer, who works in the Faculty's Department of Oncology.

"The old chemotherapy drugs required special proteins to get inside of cells to work. What our team discovered is that the new chemotherapy drugs prevented these proteins from carrying the old into the cell. No one was able to figure out why this combination of drugs didn't work, but now we have discovered what went wrong." Sawyer says the findings will guide oncologists about how drugs should be combined, or whether certain drugs should be combined at all.

"This will save us from doing millions of dollars in that have no chance of working out. These findings show oncologists we have to be careful about which drugs should be combined. You have to think about how they actually work, especially in ways which no one understood before.

"Our research was actually like peeling an onion. Once we figured out the answer to one question, then other things the drugs did make more sense. Ultimately, the findings mean we'll be able to design better combination drug therapies. We'll know which drugs to combine, and when and how drugs can be combined. This will require more precise scheduling and dosing than what we've done to date."

He stressed the only patients impacted were those in clinical trials – the therapy had not yet become common clinical practice because it wasn't working the way oncologists had hoped. And for those patients who took part in the clinical trials, the one chemotherapy was still very effective – so those patients still received excellent care and drugs that properly targeted their cancers.

Sawyer and his team are continuing their research in this area. Their research was funded by the former Alberta Cancer Board, the Alberta Cancer Foundation and Alberta Innovates – Health Solutions.

Explore further: Sanofi abandons two drugs after trial failures

Related Stories

Biologists ID new cancer weakness

November 14, 2013

About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA.

Study explains why drug may help more cancer patients

November 18, 2013

(Medical Xpress)—Recently some intriguing data has suggested that breast cancer patients whose tumors appear insensitive to a class of drugs known as anti-HER2 medications (the drug trastuzumab, marketed as Herceptin, is ...

Re-thinking cancer treatment

November 18, 2013

A new treatment approach for tackling cancer of the food pipe (oesophagus) has been developed by researchers at Cardiff and Velindre NHS Trust.

Discovery paves way for personalized cancer treatment

November 18, 2013

A prostate cancer researcher at the University of Alberta and his team have discovered how to improve currently available cancer drugs so the medication could be personalized for individual patients.

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.